Your email has been successfully added to our mailing list.

×
0.011777301927195 0.011777301927195 0.0149892933618844 0.0149892933618844 0.0149892933618844 0.0149892933618844 0.0149892933618844 -0.00963597430406851
Stock impact report

XBiotech up 13% on positive bermekimab data [Seeking Alpha]

XBiotech Inc. (XBIT) 
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
Company Research Source: Seeking Alpha
XBiotech up 13% on positive bermekimab data Thinly traded micro cap XBiotech ( XBIT +13.4% positive results Phase 2 clinical trial After seven weeks of receiving 400 mg of bermekimab once per week, 71% of treated patients achieved EASI 75 (75% reduction in AD symptoms). Patients in this cohort also experienced a 71% reduction in itching and 84% reduction in pain. By comparison, the proportions of AD patients in two Phase 3 studies who received Regeneron Pharmaceuticals ( REGN +2.1% SNY +1.5% Bermekimab Show less Read more
Impact Snapshot
Event Time:
XBIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for XBIT alerts
Opt-in for
XBIT alerts

from News Quantified
Opt-in for
XBIT alerts

from News Quantified